Browsing Tag
Alzheimer’s Disease
56 posts
Alzheimer’s blood test breakthrough raises hopes for earlier dementia risk detection
Alzheimer’s may start long before memory loss. Blood tests could shift dementia care from late diagnosis to earlier risk planning.
Is delivery, not biology, the real key to Alzheimer’s breakthroughs? Lunai Bioworks Inc. is testing it
Can Lunai Bioworks Inc. solve Alzheimer’s drug delivery challenges? Discover what its BBB platform means for CNS innovation and investor outlook.
Why CNS drug developers are paying attention to Alamar Biosciences’ latest move
How Alamar Biosciences’ Neuro 220 Panel could reshape CNS biomarker discovery and drug trials. Explore the strategic implications now.
NeuroSense Therapeutics (NASDAQ: NRSN) extends PrimeC exclusivity to 2042 with Australian patent as Phase 3 focus intensifies
Find out how NeuroSense Therapeutics’ Australian patent grant strengthens PrimeC’s long-term outlook as the ALS program advances toward Phase 3.
Neurophet bags third FDA 510(k) clearance as AI imaging tools move closer to frontline Alzheimer’s care decisions
Neurophet wins FDA clearance for AQUA AD Plus, strengthening its U.S. strategy as AI imaging becomes central to Alzheimer’s treatment decisions. Read more.
Can AI-guided delivery platforms reshape CNS drug development? Inside the Mercury Bio and Meta-Flux alliance
Mercury Bio and Meta-Flux are teaming up to tackle Parkinson's and Alzheimer's with AI-powered simulation and next-gen delivery. Can this reshape CNS drug development?
Sanofi invests up to $1bn in South Korean biotech ADEL to advance tau-based Alzheimer’s therapy
Sanofi has signed an up to $1 billion Alzheimer’s drug deal with South Korean biotech ADEL. Find out what the tau targeting strategy means for investors and patients.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025
Find out how Eisai and Biogen's LEQEMBI may slow Alzheimer’s by over 8 years in early-stage patients, as new CTAD 2025 data reveals long-term benefits.
Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025
Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape.